Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Non-Surgical Solution to Dark Circles Under the Eyes Just Got Better
  • USA - English


News provided by

Levine Communication Office

Feb 25, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


"I'm thrilled. Now with Voluma®, one of my most popular procedures is so much better. The effects last so much longer and the reversibility gives everyone great peace of mind!" said Dr. Rivkin

Post this

LOS ANGELES, CA (PRWEB) February 25, 2014 -- From the plastic surgery mecca of the world, and the foremost expert on non-invasive cosmetic procedures, comes the latest technique to safely correct dark circles under the eyes with Voluma® the newest injectable hyaluronic acid (HA). The revolutionary non-surgical blepharoplasty "Eye Lift" with Voluma® (watch video here), developed by renowned Cosmetic Surgeon Dr. Alexander Rivkin, M.D, is proven to instantly take years of unsightly aging off one's appearance making it the go-to alternative to conventional blepharoplasty. The immediate and long-lasting benefits are "turning heads" and "raising eyebrows" around the world, making it one of THE most popular procedures of the year.

One key aspect that makes Dr. Rivkin's procedure unique and attractive to patients is that unlike in traditional eyelid surgery, volume is actually replenished in the lower eyelid area. It is not removed. While many patients complain about 'bags' or "dark circles" under their eyes, Dr. Rivkin has found that the majority of people suffer from a loss (not overabundance) of fatty tissue under the eyes over time. It is this progressive hollowing of the under eye and cheek that makes people look tired and older than they are. With Dr. Rivkin's procedure, patients avoid a skeletonized, hollowed-out look and leave with an instantly smooth and youthful appearance. More importantly, Dr. Rivkin's non-surgical eyelid procedure with Voluma is a safe, cost-effective alternative to traditional eyelid surgery. It also avoids many of the inherent risks associated with traditional blepharoplasty including permanent damage to the eye, scarring, infection, and anesthesia complications. The only adverse effect of the procedure is occasional bruising, which resolves within a few days.

The second key aspect that differentiates and improves Dr. Rivkin's procedure is of course the introduction of Voluma® itself. Voluma® is the latest injectable hyaluronic acid (HA) filler that rejuvenates the face by restoring the youthful volume that is lost with time. FDA approved last year, Voluma® is part of the Juvederm product line, which has been safely and successfully providing beautiful results to patients for many years. When Voluma® filler is injected into the skin, immediate volumizing will occur, providing a youthful, rejuvenated appearance and results that last up to 2-3 years (this is several times longer duration than any other filler). Like all HA fillers, Voluma is fully reversible at any time with an enzyme called hyaluronidase. Dr. Alexander Rivkin is pleased to incorporate this latest development in filler technology to his non-surgical eyelid procedure. Unlike other facial volumizers, Voluma® carries a lower incidence of adverse effects and allergic reactions. In comparison to Sculptra®, and Radiesse®, Voluma® is associated with a lower incidence of swelling and bruising, as well as reduced occurrence of nodule formation. Additionally, clinical trials have proven that Voluma® is more effective in improving facial volume than other leading fillers. The safety advantages alone combined with the improved cosmetic results and minimal recovery time make it the "Rolls Royce" of leading fillers.

"I'm thrilled. Now with Voluma®, one of my most popular procedures is so much better. The effects last so much longer and the reversibility gives everyone great peace of mind!" said Dr. Rivkin.

Dr. Rivkin's non-surgical blepharoplasty takes less than 30 minutes on average. It is safely performed by Dr. Rivkin by injecting Voluma®, with a fine needle or cannula beneath the eyes to raise the hollowed out skin and give the cheeks their youthful roundness. This eliminates the depression between the cheek and the eyelid. Small injections are made based on a careful examination of each patients unique facial contours to determine where exactly the filler should be injected and how much should be used. Numbing cream is used to assure maximum comfort. After the injections there is sometimes minor bruising that goes away within a few days. Other than that, results are immediate, smooth, natural and last up to two to three years. Unlike traditional eyelid surgery, this temporary method allows patents to make adjustments as the face changes over time always guaranteeing a natural look.

###
About Dr. Rivkin
Dr. Rivkin is a facial cosmetic surgeon and an Assistant Clinical Professor in the Department of Medicine, Division of Dermatology at the UCLA, David Geffen School of Medicine. He is an international authority on non-surgical aesthetics and is best known for inventing and popularizing the Non-Surgical Rhinoplasty procedure. His practice, Westside Aesthetics, is focused on developing and perfecting non-invasive, non-ablative cosmetic treatments.

Dr. Rivkin received his undergraduate degree from Columbia University and his medical degree from the Yale University School of Medicine. His residency in Otolaryngology/ Head and Neck Surgery was at the University of California, San Diego, School of Medicine. He has authored numerous scientific articles and has been recognized for outstanding research achievements with grants and awards from the National Institutes for Health, the American Academy of Otolaryngology and the American College of Surgeons.

With his innovations in non-surgical cosmetic procedures, Dr. Rivkin has led the industry in a new direction and spends a significant amount of time educating other physicians around the world. In addition to teaching on the faculty at the UCLA School of Medicine, Dr. Rivkin is also a prominent member of National Teaching Faculties for Allergan, Merz, Medicis, Sanofi Aventis, Suneva and Contura. His practice is an active research center, conducting FDA trials and publishing papers on novel techniques in non-surgical aesthetics. He is a member of the American Academy of Cosmetic Surgery, American Academy of Otolaryngology, the American Society of Cosmetic Dermatology and Aesthetic Surgery, and the American Society for Laser Medicine and Surgery.

Dr. Rivkin often serves as an expert for media shows and publications, including the TODAY show, The Doctors, EXTRA, the Tyra show, Canal 5 France, The New York Times, The Washington Times, BAZAAR, ELLE Magazine and many more.

Dr. Rivkin is strongly committed to his philanthropic endeavors. He is honored to serve on the board of the New West Symphony, as well as on the boards of a number of charities including the Face Forward Foundation for Battered Women and the Lynne Cohen Foundation for Breast and Ovarian Cancer Research.

For More Information Visit: http://www.westsidemedicalspa.com/

Shannon Donnelly, Levine Communication Office, +1 (310) 300-0950 Ext: 312, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.